Screening Phase Sample Clauses

Screening Phase. 9.1.1 If both parties decide to jointly sell their interests with respect to a compound or Candidate which is still in the Screening Phase, the parties agree that the net proceeds from any sale shall be divided equally without consideration of Third Party Obligations. A party shall pay from its share of the net proceeds all Third Party Obligations such party may owe. In arriving at net proceeds, all reasonable out-of-pocket transaction costs (e.g. attorney fees) shall be deducted from gross proceeds and paid directly to the person or entity owed or reimbursed to the party who has paid the person or entity for such costs. 9.1.2 If the parties jointly license their interests in any Candidates or partially sequenced compounds during the Screening Phase, the parties agree that any revenues received with respect to such licensing shall be equally shared as described in Paragraph 9.1.1 including, without limitation, any initial payment, milestone fees or royalties.

Screening Phase. All activities described in this Section 4.1 shall end when the Screening Phase ends. SB may extend the Screening Phase upon six (6) months written notice to ArQule, provided that the parties reach agreement on terms and conditions for such extension during the six-month notice period. The Screening Phase may also extend automatically as provided in Subsection 4.2.6.

Screening Phase. The Screening Phase of the Research Program shall begin on the Effective Date and, on a Collaboration Target by Collaboration Target basis, unless extended in accordance with this Section 4.3.1, shall extend until the five (5) year anniversary of the Effective Date (the "Initial Term of the Screening Phase") unless this Agreement is earlier terminated in its entirety in accordance with Sections 11.4, 11.5, or 11.9.1 or with respect to such Collaboration Target in accordance with Section 11.7. The Initial Term of the Screening Phase of the Research Program may be extended by mutual agreement of the Parties on terms substantially the same as those set forth herein, unless otherwise agreed in writing by the Parties. On or before the day one hundred eighty (180) days before the expiration of the Initial Term of the Screening Phase of the Research Program or the then current extension thereof, as applicable, either Party may provide to the other Party written notice of its desire to extend the Screening Phase of the Research Program by one (1) additional year. Promptly after the other Party's receipt of such written notice the Parties shall commence discussions of the need and desire to extend the Screening Phase of the Research Program and if both Parties do not agree, in writing, to such extension on or before the day sixty (60) days before the expiration of the Initial Term of the Screening Phase or the then current extension thereof, the Term of the Screening Phase shall expire at the end of the Initial Term of the Screening Phase or the then current extension thereof, as applicable.

Screening Phase. Before any study-related procedures are performed, the risks of the study will be explained to a potential subject, and the subject or his/her legal representative will be required to sign an informed consent form. Screening procedures will be performed within 30 days, within the 24 hours before surgery, and after anesthesia induction, as indicated in the Time and Events Schedule that follows the Synopsis.

Screening Phase